ClinicalTrials.gg
CompletedNCT03620175Updated Jan 30, 2019

Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants

A Phase 1 interventional study of TolaSure Topical Gel in Wound Healing, sponsored by BioMendics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by BioMendics, LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2018, 7 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

TolaSure is a topical gel for the promotion of wound healing. This phase I study will assess the safety, tolerability and clinical effect of TolaSure when applied to skin wounds created by punch biopsy in healthy participants. A total of 26 healthy volunteers, males and females ages 18 years or older, will be enrolled. Subjects will monitored for safety and efficacy over the course of 2 weeks following daily topical administration of TolaSure.

02

Conditions studied

  • Wound Healing

Keywords

  • Healthy Participants
  • Skin
  • Dermal
  • Biopsy
03

In context

Lead sponsor

BioMendics, LLC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Males and Females > 18 years of age
  • Health history review
  • Physical exam
  • Blood and urine clinical chemistries
  • Pregnancy test
  • Drug screen

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic skin disorders (e.g. acne, psoriasis, dermatitis)
  • Prone to keloids or hypertrophic scarring
  • Topical or systemic antibiotics within 4 weeks of study enrollment
  • Subjects with mental illnesses
  • Diagnosed with Diabetes Type I/II
  • Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
  • History of severe vitamin or mineral deficiency
  • History of drug or alcohol abuse (as defined by the Investigator)
  • Smoking/Vaping
  • /AIDS
  • Consistently taking and/or non-steroidal anti-inflammatory drugs
  • Cancer diagnosis in the last year
  • Currently receiving chemotherapy or radiation
  • Women who are pregnant, nursing or planning a pregnancy
  • Hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields
  • Symptoms of a illness in the four weeks before treatment application that may influence the outcome of the study
  • Treatment with any agent within one month before treatment application for this trial
  • Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule
  • Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    5 Percent TolaSure Topical Gel

    Drug: TolaSure Topical Gel

  • Active comparator
    1.5 Percent TolaSure Topical Gel

    Drug: TolaSure Topical Gel

  • Active comparator
    0.5 Percent TolaSure Topical Gel

    Drug: TolaSure Topical Gel

  • Placebo comparator
    Topical Vehicle Gel

    Drug: TolaSure Topical Gel

Interventions

  • DrugTolaSure Topical Gel

    TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.

06

What researchers measure

Primary outcomes

  1. Blood and Urine Chemistries

    Absolute values and changes over time of clinical chemistries including; Absolute values and changes over time of clinical blood and urine chemistries including; Hematology and Coagulation, Coagulation, Serum Chemistry, and Urinalysis. Blood and urine analytes are measured on a per mL basis.

    Time frame: Day 1, 2, 7 and 14.

  2. Cutaneous Tolerability

    Cutaneous tolerability will include an evaluation of erythema and edema following the modified Draize scoring system. Draize scores will be recorded and changes from baseline Draize scores will be monitored over the course of the time frame. Draize Scoring System. Erythema: 0-No Erythema, 1-Slight Erythema, 2-Well Defined Erythema, 3- Moderate or Severe Erythema, 4- Severe Erythema or slight eschar formation. Edema: 0- No Edema, 1- Very Slight Edema(barely perceptible), 2-Slight Edema (well defined edges), 3-Moderate Edema (raised \>1mm), 4- Severe Edema (raised \>1mm and extending beyond the area of exposure)

    Time frame: Day 1, 2, 7 and 14.

Secondary outcomes

  1. Wound Closure

    Imaging of punch biopsies to monitor for healing and wound closure including measurement of changes in wound area (mm\^2) over time will be assessed using digital imaging and analyzed using wound tracing techniques followed by the use of appropriate statistics.

    Time frame: Day 1, 2, 7 and 14.

07

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Dec 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Aug 8, 2018
StartActual
Jul 16, 2018
Primary completionActual
Dec 12, 2018
CompletionActual
Dec 12, 2018
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03620175
Lead sponsor
BioMendics, LLC
Collaborators
University of Miami
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Jul 16, 2018
Primary completion
Dec 12, 2018
Completion
Dec 12, 2018
Last update
Jan 30, 2019

Study contacts

Karen McGuire, PhD
study director · BioMendics, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion